New York, NY, February 12, 2025 – Royalty Pharma (Nasdaq: RPRX) has entered into an agreement with Biogen to provide up to $250 million in research and development (R&D) funding for litifilimab, a first-in-class investigational biologic in Phase 3 trials for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
“Litifilimab has the potential to significantly improve treatment outcomes for lupus patients,” said Pablo Legorreta, CEO of Royalty Pharma. “We are excited to support its Phase 3 development through this funding collaboration.”
Under the agreement, Royalty Pharma will fund Biogen over six quarters in exchange for regulatory milestones and mid-single digit royalties on worldwide sales. Litifilimab has demonstrated proof of concept with a well-tolerated safety profile, and results from Phase 3 trials are expected between 2026 and 2027.
Maiwald acted as legal advisors to Royalty Pharma.
About Royalty Pharma
Founded in 1996, Royalty Pharma is a leading buyer of biopharmaceutical royalties, partnering across the industry to fund innovation. Its portfolio includes royalties on more than 35 commercial products, such as Trikafta, Evrysdi, and Imbruvica.
This text is a summary of an article published by Royalty Pharma. The full text of the article is available here.
